Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission

Rheumatology

Volumn 50, Issue 4, 2011, Pages 689-696

  Tadema, Henko ^a   Abdulahad, Wayel H ^a   Lepse, Nikola ^a   Stegeman, Coen A ^a   Kallenberg, Cees G M ^a   Heeringa, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anti neutrophil cytoplasmic antibodies; B lymphocytes; Bacterial DNA; Cytosine phosphate guanine oligodeoxynucleotide; Vasculitis

Indexed keywords

BACTERIAL DNA; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 2; NEUTROPHIL CYTOPLASMIC ANTIBODY; TOLL LIKE RECEPTOR 9;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELLS, CULTURED; DNA, BACTERIAL; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PHENOTYPE; RECURRENCE; REMISSION, SPONTANEOUS; STAPHYLOCOCCUS AUREUS; TOLL-LIKE RECEPTOR 9;

EID: 79952807884     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq375     Document Type: Article

References (39)

1. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006;2:661-70.
2. Kallenberg CG, Tadema H. Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to "autoimmunity and infection". Autoimmun Rev 2008;8: 29-32.
3. Sfriso P, Ghirardello A, Botsios C et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 2010;87:385-95.
4. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005;366:1653-66.
5. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005;366:155-68.
6. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:12-7.
7. Zycinska K, Wardyn KA, Zielonka TM, Demkow U, Traburzynski MS. Chronic crusting, nasal carriage of Staphylococcus aureus and relapse rate in pulmonary Wegener's granulomatosis. J Physiol Pharmacol 2008; 59(Suppl. 6):825-31.
8. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20.
9. Stegeman CA, Tervaert JW, Kallenberg CG. Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? Nephrol Dial Transplant 1997;12:652-5.
10. Pendergraft WF III, Preston GA, Shah RR et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004;10:72-9.
11. Kain R, Exner M, Brandes R et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008;14:1088-96.
12. Kain R, Matsui K, Exner M et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995;181:585-97.
13. Schembri MA, Kjaergaard K, Sokurenko EV, Klemm P. Molecular characterization of the Escherichia coli FimH adhesin. J Infect Dis 2001;183(Suppl. 1):S28-31.
14. Hurtado PR, Jeffs L, Nitschke J et al. CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol 2008;9:34.
15. Yi AK, Klinman DM, Martin TL, Matson S, Krieg AM. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol 1996;157: 5394-402.
16. Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
17. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003;101:4500-4.
18. Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol 2007;37:2205-13.
19. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
20. Tervaert JW, Goldschmeding R, Elema JD et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990;37: 799-806.
21. Tervaert JW, Mulder L, Stegeman C et al. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis 1993;52:115-20.
22. Lacki JK, Mackiewicz SH, Leszczynski P, Muller W. The effect of intravenous cyclophosphamide pulse on peripheral blood lymphocytes in lupus erythematosus patients. Rheumatol Int 1997;17:55-60.
23. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56.
24. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377-86.
25. Papadimitraki ED, Choulaki C, Koutala E et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006;54:3601-11.
26. Zorro S, Arias M, Riano F et al. Response to ODN-CpG by B Cells from patients with systemic lupus erythematosus correlates with disease activity. Lupus 2009;18:718-26.
27. Szodoray P, Alex P, Frank MB et al. A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis. Rheumatology 2006;45:1466-76.
28. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005;26:136-40.
29. Wrammert J, Smith K, Miller J et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008;453:667-71.
30. Clayton AR, Savage CO. Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis. Clin Exp Immunol 2003; 132:174-9.
31. Sanders JS, Stassen PM, van Rossum AP, Kallenberg CG, Stegeman CA. Risk factors for relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: tools for treatment decisions? Clin Exp Rheumatol 2004; 22(6 Suppl. 36):S94-101.
32. Muller A, Trabandt A, Gloeckner-Hofmann K et al. Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J Pathol 2000;192: 113-20.
33. Hooke DH, Gee DC, Atkins RC. Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int 1987;31:964-72.
34. Voswinkel J, Mueller A, Kraemer JA et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006;65:859-64.
35. Walsh M, Jayne D. Targeting the B cell in vasculitis. Pediatr Nephrol 2009;24:1267-75.
36. Pallan L, Savage CO, Harper L. ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol 2009;5:278-86.
37. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
38. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
39. Capolunghi F, Rosado MM, Cascioli S et al. Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology 2010;49:2281-9.